胺碘酮联合阿托伐他汀治疗非缺血性心衰伴恶性心律失常的疗效及安全性分析

目的:探讨胺碘酮联合联合阿托伐他汀治疗非缺血性心衰伴恶性心律失常的疗效及安全性分析.方法:本研究选取了180例非缺血性心衰伴恶性心律失常患者,胺碘酮组(88例)给予胺碘酮,联合用药组(92例)给予胺碘酮和阿托伐他汀,观察并记录两组患者治疗后的疗效,肿瘤坏死因子(TNF-α),白细胞介素(IL-6),高敏C反应蛋白(hs-CRP)等炎性因子,随访资料,评价胺碘酮与阿托伐他汀治疗非缺血性心衰伴恶性心律失常的疗效.结果:治疗后联合用药组有效率明显高于胺碘酮组,治疗前,两组TNF-α,IL-6,hs-CRP水平相比,差异没有统计学意义.治疗后,两组TNF-α,IL-6,hs-CRP水平均明显降低,且联合用药组上述指标均明显低于胺碘酮组;治疗后,联合用药组患者生理功能,生理职能,躯体疼痛,总体健康评分均明显高于胺碘酮组;随访6个月期间,两组在频发室性早搏、室性阵发性心动过速、心功能恶化上相比,差异没有统计学意义.联合用药组死亡率明显低于胺碘酮组.结论:胺碘酮联合阿托伐他汀对非缺血性心衰伴恶性心律失常具有较好的治疗作用,能减轻炎症反应,提高患者生活质量,降低患者病死率,值得临床推广使用.

The efficacy and safety of amiodarone combined with atorvastatin in the treatment of patients with non ischemic heart failure and malignant arrhythmia

Objective Discuss the efficacy and safety of amiodarone combined with atorvastatin in the treatment of patients with non ischemic heart failure and malignant arrhythmia.Methods180 patients with non ischemic heart failure and malig-nant arrhythmia were selected, the amiodarone group (88 cases) were given amiodarone, the combination group (92 cases) were given amiodarone and atorvastatin. The efficacy of amiodarone combined with atorvastatin in the treatment of patients with non ischemic heart failure and malignant arrhythmiawere evaluated by efficacy, TNF-α, IL-6, hs-CRP, follow-up data.ResultsAfter treatment, the effective rate of combination group were higher than that of the amiodarone group. Before treatment, there were no statistical significance on TNF-α, IL-6, hs-CRP between two group. After treatment, the TNF-α, IL-6, hs-CRP were de-creased apparently. The indexes of combination group were lower. After treatment, the physiological function, physical function, body pain and the overall health scores of combination group were higher than that of the amiodarone group. During6 months follow-up, there were no statistical significance on the frequent ventricular premature beats, paroxysmal ventricular tachycardia and deterioration of cardiac function. The mortality of combination group was significantly lower than that of the amiodarone group.ConclusionIn Summary, amiodarone combined with atorvastatin had a better therapeutic effect on non ischemic heart failure and malignant arrhythmia. It could relieve the inflammatory reaction, improve the quality of life and reduce mortality of patients. It was worthy of clinical use.